Revenue Guidance -- Management reiterated full-year fiscal 2025 revenue guidance of $26 million to $30 million and set Q4 ...
Bionano Genomics, Inc. ( BNGO) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Good day, and welcome to the Bionano Third Quarter 2025 Earnings Conference Call. Today's conference is being ...
A new technology may allow patients to recover vision for conditions that were previously thought irreversible ...
Following publication of KEYNOTE-689 Phase 3 results confirming the role of perioperative checkpoint inhibition in head and neck cancer, GeoVax announced plans for a Phase 2 trial (AdPNP-203) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback